(4) Drugs targeting immune checkpoint block are promising in the treatment of cancers [40, 41]; SYNJ2 expression was significantly positively related to plenty of immune checkpoints in several cancers, suggesting that it may have similar clinical potential as immune checkpoints. This evidence concerns the gene SYNJ2 and cancer.